History of C2 monitoring in heart and liver transplant patients treated with cyclosporine microemulsion (Q35711423)

9 August 2017

1 reference

title

History of C2 monitoring in heart and liver transplant patients treated with cyclosporine microemulsion (English)

1 reference

9 August 2017

1 reference

Cantarovich M

1

1 reference

9 August 2017

Barkun J

2

1 reference

9 August 2017

Giannetti N

3

1 reference

9 August 2017

Cecere R

4

1 reference

9 August 2017

Besner JG

5

1 reference

9 August 2017

Tchervenkov J

6

1 reference

9 August 2017

language of work or name

English

0 references

publication date

1 March 2004

1 reference

Transplantation Proceedings

9 August 2017

published in

1 reference

9 August 2017

volume

36

1 reference

9 August 2017

issue

2 Suppl

1 reference

9 August 2017

page(s)

442S-447S

1 reference

Cyclosporine-associated chronic nephropathy

9 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2004.01.004

Early and late forms of cyclosporine nephrotoxicity: studies in cardiac transplant recipients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2004.01.004

Chronic renal failure after transplantation of a nonrenal organ

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2004.01.004

Evidence for earlier stabilization of cyclosporine pharmacokinetics in de novo renal transplant patients receiving a microemulsion formulation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2004.01.004

Safety and tolerability of cyclosporine and cyclosporine microemulsion during 18 months of follow-up in stable renal transplant recipients: a report of the Canadian Neoral Renal Study Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2004.01.004

A randomized, prospective multicenter pharmacoepidemiologic study of cyclosporine microemulsion in stable renal graft recipients. Report of the Canadian Neoral Renal Transplantation Study Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2004.01.004

Oral cimetidine improves the accuracy and precision of creatinine clearance in lupus nephritis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2004.01.004

Cimetidine improves the reliability of creatinine as a marker of glomerular filtration

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2004.01.004

Clinical benefit of neoral dose monitoring with cyclosporine 2-hr post-dose levels compared with trough levels in stable heart transplant patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2004.01.004

Neoral dose monitoring with cyclosporine 2-hour postdose levels in heart transplant patients receiving anti-thymocyte globulin induction

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2004.01.004

Impact of cyclosporine 2‐h level and mycophenolate mofetil dose on clinical outcomes in de novo heart transplant patients receiving anti‐thymocyte globulin induction

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2004.01.004

Relationship between endomyocardial biopsy score and cyclosporine 2-h post-dose levels (C) in heart transplant patients receiving anti-thymocyte globulin induction

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2004.01.004

Improved clinical outcomes for liver transplant recipients using cyclosporine monitoring based on 2-hr post-dose levels (C2).

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2004.01.004

Randomized, international study of cyclosporine microemulsion absorption profiling in renal transplantation with basiliximab immunoprophylaxis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2004.01.004

Neoral C-2 monitoring in cardiac transplant patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2004.01.004

Comparison of neoral dose monitoring with cyclosporine through levels versus 2-hr postdose levels in stable liver transplant patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2004.01.004

Peak cyclosporine levels (Cmax) correlate with freedom from liver graft rejection: results of a prospective, randomized comparison of neoral and sandimmune for liver transplantation (NOF-8)

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2004.01.004

Circadian variations in cyclosporine C2 concentrations during the first 2 weeks after liver transplantation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2004.01.004

Cyclosporine inhibition of calcineurin activity in human leukocytes in vivo is rapidly reversible

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2004.01.004

Stimulated response of peripheral lymphocytes may distinguish cyclosporine effect in renal transplant recipients receiving a cyclosporine+rapamycin regimen

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2004.01.004

10.1016/J.TRANSPROCEED.2004.01.004

7 January 2021

Identifiers

DOI

1 reference

9 August 2017

1 reference